Suda Limited, (ASX: SUD) Chief Business Officer, Nick Woolfe provides an overview of the drug delivery company, its plans to commercialise low-risk pharmaceuticals, through its world-leading technology for reformulating drugs into oral sprays offering unique advantages
Suda Limited has multiple patent families covering approx. 300 widely-used off-patent drugs and its breakthrough sub-lingual spray for treatment of children with severe malaria has completed Phase III trials. With multiple oral sprays for large mainstream markets – insomnia, migraine, erectile dysfunction, chemo-induced nausea.
World-leading proprietary technology for reformulating drugs into high-value oral sprays, a pipeline of oral sprays offering superior profiles (eg: faster onset) than standard of care, and targeting large markets with short timelines for development and rapid value creation through collaborations or trade sales.
Suda anticipate first cash inflow from licensing deals in FY2016 and first royalty streams from product sales in FY2017.